Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Frontiers in Drug Discovery is Scopus-indexed (Q1, CiteScore 5), WoS ESCI, DOAJ. Published by Frontiers Media SA.
Checked against the index lists dated .
ISSN 2674-0338Verify ISSN ↗
Publisher: Frontiers Media SA
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 9 / 57 | 85th | Q1 |
| Medicine (miscellaneous) | 118 / 466 | 74th | Q2 |
| Pharmacology | 144 / 328 | 56th | Q2 |
| Drug Discovery | 74 / 161 | 54th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2021–present, best quartile Q1, CiteScore 5.
Frontiers in Drug Discovery is Q1 in Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (rank 9 of 57), Q2 in Medicine (miscellaneous) (rank 118 of 466) and Q2 in Pharmacology (rank 144 of 328), by CiteScore 2025. It is ranked in 4 subject areas in all.
Frontiers in Drug Discovery is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5, which places it in quartile Q1 at the 85th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.873, quartile Q1, with an H-index of 15.
The publisher lists an article processing charge of about US$2,353 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Frontiers in Drug Discovery is published by Frontiers Media SA. Its ISSN is 2674-0338.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Frontiers in Drug Discovery has an h-index of 19 and a 2-year mean of 6.24 citations per paper (OpenAlex). Its Scopus CiteScore is 5, quartile Q1. On 2-year citations it ranks #4 of 52 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (miscellaneous).
Frontiers in Drug Discovery published 19 papers in 2025; its busiest recent year was 2022 with 48. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2023–2026), authors are most often from United States (37%), Italy (9.1%) and Mexico (8.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.